Paper1985243
Prognostic value of immunocytologic detection of bone marrow metastases in neuroblastoma.
Moss TJ and 5 others. N Engl J Med, 1991. Cited by 232 papers, by iCite.
Cite this record
ConductScience Library. Prognostic value of immunocytologic detection of bone marrow metastases in neuroblastoma. Papers, record 1985243. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/1985243
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics14
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Bone Marrow | Major topic |
| Neuroblastoma | Major topic |
| Age Factors | |
| Antibodies, Monoclonal | |
| Biopsy | |
| Humans | |
| Immunoenzyme Techniques | |
| Neoplasm Metastasis | |
| Neoplasm Staging | |
| Prognosis | |
| Reproducibility of Results | |
| Sensitivity and Specificity | |
| Trephining | |
| Tumor Cells, Cultured |
Source PubMed
Grants5
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by | Source |
|---|---|---|---|---|---|
| CA-16042 | NCI NIH HHS | United States | P01CA016042 | PubMed and NIH | NIH RePORTER |
| CA-22794 | NCI NIH HHS | United States | R01CA022794 | PubMed and NIH | NIH RePORTER |
| CA-27678 | NCI NIH HHS | United States | R10CA027678 | PubMed and NIH | NIH RePORTER |
| P30CA016042 | NIH | NIH RePORTER | |||
| U10CA027678 | NIH | NIH RePORTER |
Cited by41
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 232 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42818635 | Quantitative and sensitive neuroblastoma minimal residual disease detection using extrachromosomal DNA (ecDNA) breakpoints. | bioRxiv | 2026 | https://conductscience.org/library/papers/42818635 | PubMed |
| 40483504 | Epithelial-to-mesenchymal transition (EMT) and cancer metastasis: the status quo of methods and experimental models 2025. | Mol Cancer | 2025 | https://conductscience.org/library/papers/40483504 | PubMed |
| 40450177 | Evaluation of Minimal Residual Disease in Patients with Neuroblastoma. | Mol Diagn Ther | 2025 | https://conductscience.org/library/papers/40450177 | PubMed |
| 37834874 | A Multi-Color Flow Cytometric Assay for Quantifying Dinutuximab Binding to Neuroblastoma Cells in Tumor, Bone Marrow, and Blood. | J Clin Med | 2023 | https://conductscience.org/library/papers/37834874 | PubMed |
| 37284114 | Evaluation of iodine-123-labeled metaiodobenzylguanidine single-photon emission computed tomography/computed tomography based on the International Society of Pediatric Oncology Europe Neuroblastoma score in children with neuroblastoma. | Quant Imaging Med Surg | 2023 | https://conductscience.org/library/papers/37284114 | PubMed |
| 36176417 | Pro-metastatic and mesenchymal gene expression signatures characterize circulating tumor cells of neuroblastoma patients with bone marrow metastases and relapse. | Front Oncol | 2022 | https://conductscience.org/library/papers/36176417 | PubMed |
| 34445807 | Neuroblastoma GD2 Expression and Computational Analysis of Aptamer-Based Bioaffinity Targeting. | Int J Mol Sci | 2021 | https://conductscience.org/library/papers/34445807 | PubMed |
| 31214500 | Dynamics of Minimal Residual Disease in Neuroblastoma Patients. | Front Oncol | 2019 | https://conductscience.org/library/papers/31214500 | PubMed |
| 30613134 | Spotlight on dinutuximab in the treatment of high-risk neuroblastoma: development and place in therapy. | Biologics | 2019 | https://conductscience.org/library/papers/30613134 | PubMed |
| 26840262 | PHOX2B is a suppressor of neuroblastoma metastasis. | Oncotarget | 2016 | https://conductscience.org/library/papers/26840262 | PubMed |
| 25559819 | Bone marrow minimal residual disease was an early response marker and a consistent independent predictor of survival after anti-GD2 immunotherapy. | J Clin Oncol | 2015 | https://conductscience.org/library/papers/25559819 | PubMed |
| 25467309 | Bone marrows from neuroblastoma patients: an excellent source for tumor genome analyses. | Mol Oncol | 2015 | https://conductscience.org/library/papers/25467309 | PubMed |
| 24255631 | Morphologic alteration of metastatic neuroblastic tumor in bone marrow after chemotherapy. | Korean J Pathol | 2013 | https://conductscience.org/library/papers/24255631 | PubMed |
| 21971567 | Immunology and immunotherapy of neuroblastoma. | Semin Cancer Biol | 2011 | https://conductscience.org/library/papers/21971567 | PubMed |
| 21769682 | Cellular kinetics of neuroblastoma and the role of surgery. | Pediatr Surg Int | 2011 | https://conductscience.org/library/papers/21769682 | PubMed |
| 21037966 | Anti-GD2 Strategy in the Treatment of Neuroblastoma. | Drugs Future | 2010 | https://conductscience.org/library/papers/21037966 | PubMed |
| 20049927 | Peripheral blood stem cell support for multiple cycles of dose intensive induction therapy is feasible with little risk of tumor contamination in advanced stage neuroblastoma: a report from the Childrens Oncology Group. | Pediatr Blood Cancer | 2010 | https://conductscience.org/library/papers/20049927 | PubMed |
| 19411762 | Valpha24-invariant NKT cells mediate antitumor activity via killing of tumor-associated macrophages. | J Clin Invest | 2009 | https://conductscience.org/library/papers/19411762 | PubMed |
| 19401690 | Consensus criteria for sensitive detection of minimal neuroblastoma cells in bone marrow, blood and stem cell preparations by immunocytology and QRT-PCR: recommendations by the International Neuroblastoma Risk Group Task Force. | Br J Cancer | 2009 | https://conductscience.org/library/papers/19401690 | PubMed |
| 18834405 | The urokinase receptor (u-PAR)--a link between tumor cell dormancy and minimal residual disease in bone marrow? | APMIS | 2008 | https://conductscience.org/library/papers/18834405 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Trials
- Comments and corrections
- References
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/1985243
GET https://conductscience.org/api/papers/v1/1985243/cited_by?page=2